> top > docs > PMC:3586680 > spans > 1137-2220 > annotations

PMC:3586680 / 1137-2220 JSONTXT

Annnotations TAB JSON ListView MergeView

bionlp-st-ge-2016-test-tees

Id Subject Object Predicate Lexical cue
T2272 914-926 Protein denotes STAT3 kinase
T2271 856-863 Protein denotes histone

bionlp-st-ge-2016-spacy-parsed

Id Subject Object Predicate Lexical cue
T2722 1082-1083 . denotes .
T2721 1081-1082 -RRB- denotes )
T2720 1076-1081 JJ denotes 2012b
T2719 1074-1075 , denotes ,
T2718 1071-1074 FW denotes al.
T2717 1068-1070 FW denotes et
T2716 1062-1067 NNP denotes Zhang
T2715 1060-1061 : denotes ;
T2714 1056-1060 CD denotes 2012
T2713 1054-1055 , denotes ,
T2712 1051-1054 FW denotes al.
T2711 1048-1050 FW denotes et
T2710 1040-1047 NNP denotes Kohsaka
T2709 1038-1039 : denotes ;
T2708 1034-1038 CD denotes 2012
T2707 1032-1033 , denotes ,
T2706 1029-1032 FW denotes al.
T2705 1026-1028 FW denotes et
T2704 1018-1025 NNP denotes Kitange
T2703 1016-1017 : denotes ;
T2702 1012-1016 CD denotes 2012
T2701 1010-1011 , denotes ,
T2700 1002-1010 NNP denotes Bjerkvig
T2699 998-1001 CC denotes and
T2698 986-997 NNP denotes Johannessen
T2697 984-985 : denotes ;
T2696 980-984 CD denotes 2012
T2695 978-979 , denotes ,
T2694 975-978 FW denotes al.
T2693 972-974 FW denotes et
T2692 964-971 NNP denotes Happold
T2691 962-963 : denotes ;
T2690 958-962 CD denotes 2012
T2689 956-957 , denotes ,
T2688 953-956 FW denotes al.
T2687 950-952 FW denotes et
T2686 945-949 NNP denotes Haar
T2685 944-945 -LRB- denotes (
T2684 937-943 NNS denotes others
T2683 932-936 JJ denotes many
T2682 928-931 CC denotes and
T2681 926-927 , denotes ,
T2680 920-926 NN denotes kinase
T2679 914-919 CD denotes STAT3
T2678 912-913 , denotes ,
T2677 902-912 NN denotes transition
T2676 879-901 JJ denotes epithelial-mesenchymal
T2675 877-878 , denotes ,
T2674 864-877 NN denotes deacetylation
T2673 856-863 NN denotes histone
T2672 854-855 , denotes ,
T2671 847-854 NN denotes hypoxia
T2670 841-846 IN denotes under
T2669 835-840 NNS denotes cells
T2668 829-834 NN denotes tumor
T2667 827-828 , denotes ,
T2666 821-827 NN denotes repair
T2665 814-820 NN denotes damage
T2664 810-813 NNP denotes DNA
T2663 808-809 , denotes ,
T2662 802-808 NN denotes efflux
T2661 797-801 NN denotes drug
T2660 795-796 , denotes ,
T2659 786-795 NNS denotes microRNAs
T2658 784-785 , denotes ,
T2657 779-784 NNS denotes cells
T2656 774-778 NN denotes stem
T2655 767-773 NN denotes cancer
T2654 759-766 VB denotes include
T2653 755-758 MD denotes may
T2652 749-754 WDT denotes which
T2651 747-748 , denotes ,
T2650 737-747 NN denotes resistance
T2649 733-736 NNP denotes TMZ
T2648 729-732 DT denotes the
T2647 726-728 IN denotes in
T2646 717-725 VBN denotes involved
T2645 713-716 VBP denotes are
T2644 702-712 NNS denotes mechanisms
T2643 693-701 JJ denotes Multiple
T2642 691-692 . denotes .
T2641 690-691 -RRB- denotes )
T2562 287-288 -LRB- denotes (
T2561 285-286 NN denotes %
T2560 282-285 CD denotes 9.8
T2559 277-281 RB denotes only
T2558 274-276 VBZ denotes is
T2557 270-273 NNP denotes GBM
T2556 266-269 IN denotes for
T2555 261-265 NN denotes rate
T2554 252-260 NN denotes survival
T2553 245-251 JJ denotes 5-year
T2552 237-244 JJ denotes overall
T2551 233-236 DT denotes the
T2550 229-232 CC denotes and
T2549 227-228 , denotes ,
T2548 221-227 NNS denotes months
T2547 216-220 CD denotes 14.6
T2546 213-215 VBZ denotes is
T2545 202-212 NN denotes expectancy
T2544 193-201 NN denotes survival
T2543 185-192 JJ denotes average
T2542 181-184 DT denotes the
T2541 177-180 CC denotes and
T2540 175-176 , denotes ,
T2539 169-175 JJ denotes lethal
T2538 162-168 RB denotes highly
T2537 159-161 VBZ denotes is
T2536 157-158 -RRB- denotes )
T2535 154-157 NNP denotes GBM
T2534 153-154 -LRB- denotes (
T2533 140-152 NNP denotes Glioblastoma
T2532 138-139 . denotes .
T2531 137-138 -RRB- denotes )
T2530 133-137 CD denotes 2012
T2529 131-132 , denotes ,
T2528 128-131 FW denotes al.
T2527 125-127 FW denotes et
T2526 118-124 NNP denotes Silber
T2525 116-117 : denotes ;
T2524 112-116 CD denotes 2009
T2523 110-111 , denotes ,
T2522 107-110 FW denotes al.
T2521 104-106 FW denotes et
T2520 98-103 NNP denotes Stupp
T2519 96-97 : denotes ;
T2518 92-96 CD denotes 2000
T2517 90-91 , denotes ,
T2516 87-90 FW denotes al.
T2515 84-86 FW denotes et
T2514 75-83 NNP denotes Friedman
T2513 74-75 -LRB- denotes (
T2512 65-73 RB denotes annually
T2511 60-64 NNP denotes U.S.
T2510 56-59 DT denotes the
T2509 53-55 IN denotes in
T2508 44-52 NNS denotes patients
T2507 40-43 JJ denotes new
T2506 33-39 CD denotes 12,500
T2505 24-32 VBZ denotes afflicts
T2504 13-23 JJ denotes multiforme
T2503 0-12 NNP denotes Glioblastoma
T2640 686-690 CD denotes 2010
T2639 684-685 , denotes ,
T2638 675-684 NNP denotes Nishikawa
T2637 673-674 : denotes ;
T2636 669-673 CD denotes 2000
T2635 667-668 , denotes ,
T2634 664-667 FW denotes al.
T2633 661-663 FW denotes et
T2632 652-660 NNP denotes Friedman
T2631 651-652 -LRB- denotes (
T2630 649-650 -RRB- denotes )
T2629 646-649 NNP denotes TMZ
T2628 645-646 -LRB- denotes (
T2627 632-644 NN denotes temozolomide
T2626 626-631 NN denotes agent
T2625 615-625 NN denotes alkylating
T2624 600-614 JJ denotes monofunctional
T2623 596-599 DT denotes the
T2622 591-595 IN denotes with
T2621 581-590 NN denotes treatment
T2620 577-580 CC denotes and
T2619 575-576 , denotes ,
T2618 566-575 NN denotes radiation
T2617 564-565 , denotes ,
T2616 557-564 NN denotes surgery
T2615 547-556 NN denotes debulking
T2614 539-546 NN denotes maximum
T2613 530-538 VBZ denotes includes
T2612 523-529 RB denotes mainly
T2611 519-522 NNP denotes GBM
T2610 515-518 IN denotes for
T2609 507-514 NN denotes therapy
T2608 498-506 JJ denotes standard
T2607 490-497 JJ denotes current
T2606 486-489 DT denotes The
T2605 484-485 . denotes .
T2604 483-484 -RRB- denotes )
T2603 479-483 CD denotes 2012
T2602 477-478 , denotes ,
T2601 474-477 FW denotes al.
T2600 471-473 FW denotes et
T2599 463-470 NNP denotes Happold
T2598 461-462 : denotes ;
T2597 457-461 CD denotes 2012
T2596 455-456 , denotes ,
T2595 452-455 FW denotes al.
T2594 449-451 FW denotes et
T2593 444-448 NNP denotes Haar
T2592 443-444 -LRB- denotes (
T2591 434-442 NNS denotes patients
T2590 431-433 IN denotes in
T2589 426-430 VBN denotes seen
T2588 415-425 RB denotes frequently
T2587 411-414 VBP denotes are
T2586 403-410 NN denotes relapse
T2585 396-402 NN denotes cancer
T2584 392-395 CC denotes and
T2583 381-391 NNS denotes modalities
T2582 369-380 JJ denotes therapeutic
T2581 361-368 JJ denotes current
T2580 358-360 TO denotes to
T2579 347-357 NN denotes resistance
T2578 344-346 IN denotes of
T2577 337-343 NNS denotes levels
T2576 332-336 JJ denotes High
T2575 330-331 . denotes .
T2574 329-330 -RRB- denotes )
T2573 325-329 CD denotes 2009
T2572 323-324 , denotes ,
T2571 320-323 FW denotes al.
T2570 317-319 FW denotes et
T2569 311-316 NNP denotes Stupp
T2568 309-310 : denotes ;
T2567 305-309 CD denotes 2000
T2566 303-304 , denotes ,
T2565 300-303 FW denotes al.
T2564 297-299 FW denotes et
T2563 288-296 NNP denotes Friedman
R1576 T2518 T2516 npadvmod 2000,al.
R1577 T2519 T2516 punct ;,al.
R1578 T2520 T2522 compound Stupp,al.
R1579 T2521 T2522 compound et,al.
R1580 T2503 T2504 compound Glioblastoma,multiforme
R1581 T2522 T2505 prep al.,afflicts
R1582 T2504 T2505 nsubj multiforme,afflicts
R1583 T2505 T2528 ccomp afflicts,al.
R1584 T2523 T2522 punct ",",al.
R1585 T2506 T2508 nummod "12,500",patients
R1586 T2524 T2522 npadvmod 2009,al.
R1587 T2507 T2508 amod new,patients
R1588 T2508 T2505 dobj patients,afflicts
R1589 T2509 T2508 prep in,patients
R1590 T2510 T2511 det the,U.S.
R1591 T2525 T2528 punct ;,al.
R1592 T2511 T2509 pobj U.S.,in
R1593 T2512 T2505 advmod annually,afflicts
R1594 T2526 T2528 compound Silber,al.
R1595 T2527 T2528 compound et,al.
R1596 T2528 T2528 ROOT al.,al.
R1597 T2513 T2516 punct (,al.
R1598 T2529 T2528 punct ",",al.
R1599 T2514 T2516 nmod Friedman,al.
R1600 T2515 T2516 nmod et,al.
R1601 T2530 T2528 npadvmod 2012,al.
R1602 T2516 T2522 compound al.,al.
R1603 T2517 T2516 punct ",",al.
R1604 T2531 T2528 punct ),al.
R1605 T2532 T2528 punct .,al.
R1606 T2533 T2537 nsubj Glioblastoma,is
R1607 T2534 T2535 punct (,GBM
R1608 T2570 T2571 compound et,al.
R1609 T2571 T2558 attr al.,is
R1610 T2535 T2533 appos GBM,Glioblastoma
R1611 T2572 T2571 punct ",",al.
R1612 T2573 T2571 npadvmod 2009,al.
R1613 T2574 T2558 punct ),is
R1614 T2536 T2533 punct ),Glioblastoma
R1615 T2575 T2546 punct .,is
R1616 T2576 T2577 amod High,levels
R1617 T2537 T2537 ROOT is,is
R1618 T2577 T2589 nsubjpass levels,seen
R1619 T2578 T2577 prep of,levels
R1620 T2579 T2578 pobj resistance,of
R1621 T2538 T2539 advmod highly,lethal
R1622 T2580 T2579 prep to,resistance
R1623 T2581 T2583 amod current,modalities
R1624 T2582 T2583 amod therapeutic,modalities
R1625 T2539 T2537 acomp lethal,is
R1626 T2583 T2580 pobj modalities,to
R1627 T2584 T2583 cc and,modalities
R1628 T2585 T2586 compound cancer,relapse
R1629 T2586 T2583 conj relapse,modalities
R1630 T2540 T2537 punct ",",is
R1631 T2587 T2589 auxpass are,seen
R1632 T2588 T2589 advmod frequently,seen
R1633 T2541 T2537 cc and,is
R1634 T2589 T2601 ccomp seen,al.
R1635 T2542 T2545 det the,expectancy
R1636 T2590 T2589 prep in,seen
R1637 T2543 T2545 amod average,expectancy
R1638 T2591 T2590 pobj patients,in
R1639 T2544 T2545 compound survival,expectancy
R1640 T2545 T2546 nsubj expectancy,is
R1641 T2592 T2595 punct (,al.
R1642 T2546 T2537 conj is,is
R1643 T2593 T2595 nmod Haar,al.
R1644 T2594 T2595 nmod et,al.
R1645 T2595 T2601 dep al.,al.
R1646 T2547 T2548 nummod 14.6,months
R1647 T2596 T2595 punct ",",al.
R1648 T2597 T2595 npadvmod 2012,al.
R1649 T2548 T2546 attr months,is
R1650 T2598 T2601 punct ;,al.
R1651 T2599 T2601 compound Happold,al.
R1652 T2600 T2601 compound et,al.
R1653 T2549 T2546 punct ",",is
R1654 T2601 T2601 ROOT al.,al.
R1655 T2602 T2601 punct ",",al.
R1656 T2603 T2601 npadvmod 2012,al.
R1657 T2604 T2601 punct ),al.
R1658 T2605 T2601 punct .,al.
R1659 T2606 T2609 det The,therapy
R1660 T2550 T2546 cc and,is
R1661 T2607 T2609 amod current,therapy
R1662 T2608 T2609 amod standard,therapy
R1663 T2609 T2613 nsubj therapy,includes
R1664 T2551 T2555 det the,rate
R1665 T2610 T2609 prep for,therapy
R1666 T2611 T2610 pobj GBM,for
R1667 T2612 T2613 advmod mainly,includes
R1668 T2552 T2555 amod overall,rate
R1669 T2613 T2613 ROOT includes,includes
R1670 T2614 T2616 amod maximum,surgery
R1671 T2615 T2616 compound debulking,surgery
R1672 T2553 T2555 amod 5-year,rate
R1673 T2616 T2613 dobj surgery,includes
R1674 T2617 T2616 punct ",",surgery
R1675 T2618 T2616 conj radiation,surgery
R1676 T2554 T2555 compound survival,rate
R1677 T2619 T2618 punct ",",radiation
R1678 T2620 T2618 cc and,radiation
R1679 T2555 T2558 nsubj rate,is
R1680 T2621 T2618 conj treatment,radiation
R1681 T2622 T2616 prep with,surgery
R1682 T2623 T2626 det the,agent
R1683 T2624 T2626 amod monofunctional,agent
R1684 T2556 T2555 prep for,rate
R1685 T2625 T2626 amod alkylating,agent
R1686 T2626 T2627 compound agent,temozolomide
R1687 T2627 T2622 pobj temozolomide,with
R1688 T2557 T2556 pobj GBM,for
R1689 T2628 T2627 punct (,temozolomide
R1690 T2629 T2627 appos TMZ,temozolomide
R1691 T2558 T2546 conj is,is
R1692 T2630 T2627 punct ),temozolomide
R1693 T2631 T2634 punct (,al.
R1694 T2632 T2634 compound Friedman,al.
R1695 T2559 T2560 advmod only,9.8
R1696 T2633 T2634 nmod et,al.
R1697 T2634 T2638 compound al.,Nishikawa
R1698 T2560 T2561 nummod 9.8,%
R1699 T2635 T2634 punct ",",al.
R1700 T2636 T2634 dep 2000,al.
R1701 T2637 T2634 punct ;,al.
R1702 T2561 T2558 attr %,is
R1703 T2638 T2616 appos Nishikawa,surgery
R1704 T2639 T2638 punct ",",Nishikawa
R1705 T2640 T2638 npadvmod 2010,Nishikawa
R1706 T2641 T2638 punct ),Nishikawa
R1707 T2642 T2613 punct .,includes
R1708 T2643 T2644 amod Multiple,mechanisms
R1709 T2562 T2565 punct (,al.
R1710 T2644 T2646 nsubjpass mechanisms,involved
R1711 T2645 T2646 auxpass are,involved
R1712 T2646 T2718 ccomp involved,al.
R1713 T2647 T2646 prep in,involved
R1714 T2563 T2565 compound Friedman,al.
R1715 T2648 T2650 det the,resistance
R1716 T2649 T2650 compound TMZ,resistance
R1717 T2650 T2647 pobj resistance,in
R1718 T2564 T2565 nmod et,al.
R1719 T2651 T2650 punct ",",resistance
R1720 T2652 T2654 nsubj which,include
R1721 T2653 T2654 aux may,include
R1722 T2565 T2558 parataxis al.,is
R1723 T2654 T2650 relcl include,resistance
R1724 T2655 T2657 compound cancer,cells
R1725 T2656 T2657 compound stem,cells
R1726 T2566 T2565 punct ",",al.
R1727 T2657 T2654 dobj cells,include
R1728 T2658 T2657 punct ",",cells
R1729 T2659 T2657 conj microRNAs,cells
R1730 T2567 T2565 npadvmod 2000,al.
R1731 T2660 T2659 punct ",",microRNAs
R1732 T2661 T2662 compound drug,efflux
R1733 T2662 T2659 conj efflux,microRNAs
R1734 T2663 T2662 punct ",",efflux
R1735 T2568 T2558 punct ;,is
R1736 T2664 T2666 compound DNA,repair
R1737 T2665 T2666 compound damage,repair
R1738 T2666 T2662 conj repair,efflux
R1739 T2569 T2571 compound Stupp,al.
R1741 T2667 T2666 punct ",",repair
R1742 T2668 T2669 compound tumor,cells
R1744 T2669 T2659 conj cells,microRNAs
R1746 T2670 T2654 prep under,include
R1748 T2671 T2670 pobj hypoxia,under
R1751 T2672 T2671 punct ",",hypoxia
R1753 T2673 T2674 compound histone,deacetylation
R1754 T2674 T2671 appos deacetylation,hypoxia
R1755 T2675 T2674 punct ",",deacetylation
R1756 T2676 T2677 amod epithelial-mesenchymal,transition
R1757 T2677 T2674 appos transition,deacetylation
R1758 T2678 T2677 punct ",",transition
R1759 T2679 T2680 nummod STAT3,kinase
R1761 T2680 T2677 conj kinase,transition
R1762 T2681 T2680 punct ",",kinase
R1764 T2682 T2680 cc and,kinase
R1765 T2683 T2684 amod many,others
R1766 T2684 T2680 conj others,kinase
R1768 T2685 T2684 punct (,others
R1769 T2686 T2688 compound Haar,al.
R1770 T2687 T2688 nmod et,al.
R1772 T2688 T2684 appos al.,others
R1773 T2689 T2688 punct ",",al.
R1775 T2690 T2688 npadvmod 2012,al.
R1776 T2691 T2684 punct ;,others
R1777 T2692 T2694 compound Happold,al.
R1779 T2693 T2694 compound et,al.
R1780 T2694 T2684 conj al.,others
R1781 T2695 T2694 punct ",",al.
R1783 T2696 T2694 npadvmod 2012,al.
R1784 T2697 T2718 punct ;,al.
R1785 T2698 T2718 dep Johannessen,al.
R1787 T2699 T2698 cc and,Johannessen
R1788 T2700 T2698 conj Bjerkvig,Johannessen
R1789 T2701 T2700 punct ",",Bjerkvig
R1790 T2702 T2700 npadvmod 2012,Bjerkvig
R1792 T2703 T2700 punct ;,Bjerkvig
R1793 T2704 T2706 compound Kitange,al.
R1794 T2705 T2706 compound et,al.
R1796 T2706 T2700 conj al.,Bjerkvig
R1797 T2707 T2706 punct ",",al.
R1798 T2708 T2706 npadvmod 2012,al.
R1800 T2709 T2718 punct ;,al.
R1801 T2710 T2712 compound Kohsaka,al.
R1802 T2711 T2712 compound et,al.
R1804 T2712 T2718 ccomp al.,al.
R1805 T2713 T2712 punct ",",al.
R1806 T2714 T2712 npadvmod 2012,al.
R1807 T2715 T2718 punct ;,al.
R1808 T2716 T2718 compound Zhang,al.
R1809 T2717 T2718 nmod et,al.
R1811 T2718 T2718 ROOT al.,al.
R1812 T2719 T2720 punct ",",2012b
R1814 T2720 T2718 amod 2012b,al.
R1816 T2721 T2720 punct ),2012b
R1817 T2722 T2718 punct .,al.

bionlp-st-ge-2016-test-ihmc

Id Subject Object Predicate Lexical cue
T2488 288-302 Entity denotes Friedman et al
T2466 118-124 Entity denotes Silber
T2465 596-650 Entity denotes the monofunctional alkylating agent temozolomide (TMZ)
T2463 444-454 Entity denotes Haar et al
T2456 733-736 Entity denotes TMZ
T2438 767-796 Entity denotes cancer stem cells, microRNAs,
T2429 829-936 Entity denotes tumor cells under hypoxia, histone deacetylation, epithelial-mesenchymal transition, STAT3 kinase, and many
T2412 810-813 Entity denotes DNA
T2405 914-926 Protein denotes STAT3 kinase
T2400 615-631 Entity denotes alkylating agent
T2399 914-919 Protein denotes STAT3
T2391 646-649 Entity denotes TMZ
T2373 797-801 Entity denotes drug

bionlp-st-ge-2016-uniprot

Id Subject Object Predicate Lexical cue
T2139 914-919 http://www.uniprot.org/uniprot/P40763 denotes STAT3

pmc-enju-pas

Id Subject Object Predicate Lexical cue
T1086 937-943 NN denotes others
T1123 1081-1082 -RRB- denotes )
T1122 1076-1081 NN denotes 2012b
T1121 1074-1075 -COMMA- denotes ,
T1120 1071-1074 FW denotes al.
T1119 1068-1070 FW denotes et
T1118 1062-1067 NNP denotes Zhang
T1117 1060-1061 -COLON- denotes ;
T1116 1056-1060 CD denotes 2012
T1115 1054-1055 -COMMA- denotes ,
T1114 1051-1054 FW denotes al.
T1113 1048-1050 FW denotes et
T1112 1040-1047 NNP denotes Kohsaka
T1111 1038-1039 -COLON- denotes ;
T1110 1034-1038 CD denotes 2012
T1109 1032-1033 -COMMA- denotes ,
T1108 1029-1032 FW denotes al.
T1107 1026-1028 FW denotes et
T1106 1018-1025 NNP denotes Kitange
T1105 1016-1017 -COLON- denotes ;
T1085 932-936 JJ denotes many
T1084 928-931 CC denotes and
T1083 926-927 -COMMA- denotes ,
T1082 920-926 NN denotes kinase
T1081 914-919 NN denotes STAT3
T1080 912-913 -COMMA- denotes ,
T1079 902-912 NN denotes transition
T1078 879-901 JJ denotes epithelial-mesenchymal
T1077 877-878 -COMMA- denotes ,
T1076 864-877 NN denotes deacetylation
T1075 856-863 NN denotes histone
T1074 854-855 -COMMA- denotes ,
T1073 847-854 NN denotes hypoxia
T1072 841-846 IN denotes under
T1071 835-840 NN denotes cells
T1070 829-834 NN denotes tumor
T1069 827-828 -COMMA- denotes ,
T1068 821-827 NN denotes repair
T1067 814-820 NN denotes damage
T1066 810-813 NN denotes DNA
T1065 808-809 -COMMA- denotes ,
T1064 802-808 NN denotes efflux
T1063 797-801 NN denotes drug
T1062 795-796 -COMMA- denotes ,
T1061 786-795 NN denotes microRNAs
T1060 784-785 -COMMA- denotes ,
T1059 779-784 NN denotes cells
T1058 774-778 NN denotes stem
T1057 767-773 NN denotes cancer
T1056 759-766 VB denotes include
T1055 755-758 MD denotes may
T1054 749-754 WDT denotes which
T1053 747-748 -COMMA- denotes ,
T1052 737-747 NN denotes resistance
T1051 733-736 NN denotes TMZ
T1050 729-732 DT denotes the
T1049 726-728 IN denotes in
T1048 717-725 VB denotes involved
T1047 713-716 VB denotes are
T1046 702-712 NN denotes mechanisms
T1045 693-701 JJ denotes Multiple
T1044 690-691 -RRB- denotes )
T1043 686-690 CD denotes 2010
T1042 684-685 -COMMA- denotes ,
T1041 675-684 NNP denotes Nishikawa
T1040 673-674 -COLON- denotes ;
T1039 669-673 CD denotes 2000
T1038 667-668 -COMMA- denotes ,
T1037 664-667 FW denotes al.
T1036 661-663 FW denotes et
T1035 652-660 NNP denotes Friedman
T1034 651-652 -LRB- denotes (
T1033 649-650 -RRB- denotes )
T1032 646-649 NN denotes TMZ
T1031 645-646 -LRB- denotes (
T1030 632-644 NN denotes temozolomide
T1029 626-631 NN denotes agent
T1028 615-625 VB denotes alkylating
T1027 600-614 JJ denotes monofunctional
T1026 596-599 DT denotes the
T1025 591-595 IN denotes with
T1024 581-590 NN denotes treatment
T1023 577-580 CC denotes and
T1022 575-576 -COMMA- denotes ,
T1021 566-575 NN denotes radiation
T1020 564-565 -COMMA- denotes ,
T1019 557-564 NN denotes surgery
T1018 547-556 VB denotes debulking
T1017 539-546 JJ denotes maximum
T1016 530-538 VB denotes includes
T1015 523-529 RB denotes mainly
T1014 519-522 NN denotes GBM
T1013 515-518 IN denotes for
T1012 507-514 NN denotes therapy
T1011 498-506 JJ denotes standard
T1010 490-497 JJ denotes current
T1009 486-489 DT denotes The
T1008 483-484 -RRB- denotes )
T1007 479-483 CD denotes 2012
T1006 477-478 -COMMA- denotes ,
T1005 474-477 FW denotes al.
T1004 471-473 FW denotes et
T1003 463-470 NNP denotes Happold
T1002 461-462 -COLON- denotes ;
T1001 457-461 CD denotes 2012
T1000 455-456 -COMMA- denotes ,
T999 452-455 FW denotes al.
T998 449-451 FW denotes et
T997 444-448 NNP denotes Haar
T996 443-444 -LRB- denotes (
T995 434-442 NN denotes patients
T994 431-433 IN denotes in
T993 426-430 VB denotes seen
T992 415-425 RB denotes frequently
T991 411-414 VB denotes are
T990 403-410 NN denotes relapse
T989 396-402 NN denotes cancer
T988 392-395 CC denotes and
T987 381-391 NN denotes modalities
T986 369-380 JJ denotes therapeutic
T985 361-368 JJ denotes current
T984 358-360 TO denotes to
T983 347-357 NN denotes resistance
T982 344-346 IN denotes of
T981 337-343 NN denotes levels
T980 332-336 JJ denotes High
T979 329-330 -RRB- denotes )
T978 325-329 CD denotes 2009
T977 323-324 -COMMA- denotes ,
T976 320-323 FW denotes al.
T975 317-319 FW denotes et
T974 311-316 NNP denotes Stupp
T973 309-310 -COLON- denotes ;
T972 305-309 CD denotes 2000
T971 303-304 -COMMA- denotes ,
T970 300-303 FW denotes al.
T969 297-299 FW denotes et
T968 288-296 NNP denotes Friedman
T967 287-288 -LRB- denotes (
T966 285-286 NN denotes %
T965 282-285 CD denotes 9.8
T964 277-281 RB denotes only
T963 274-276 VB denotes is
T962 270-273 NN denotes GBM
T961 266-269 IN denotes for
T960 261-265 NN denotes rate
T959 252-260 NN denotes survival
T958 245-251 JJ denotes 5-year
T957 237-244 JJ denotes overall
T956 233-236 DT denotes the
T955 229-232 CC denotes and
T954 227-228 -COMMA- denotes ,
T953 216-227 NN denotes 14.6 months
T952 213-215 VB denotes is
T951 202-212 NN denotes expectancy
T950 193-201 NN denotes survival
T949 185-192 JJ denotes average
T948 181-184 DT denotes the
T947 177-180 CC denotes and
T946 175-176 -COMMA- denotes ,
T945 169-175 JJ denotes lethal
T944 162-168 RB denotes highly
T943 159-161 VB denotes is
T942 157-158 -RRB- denotes )
T941 154-157 NN denotes GBM
T940 153-154 -LRB- denotes (
T939 140-152 NN denotes Glioblastoma
T938 137-138 -RRB- denotes )
T937 133-137 CD denotes 2012
T936 131-132 -COMMA- denotes ,
T935 128-131 FW denotes al.
T934 125-127 FW denotes et
T933 118-124 NNP denotes Silber
T932 116-117 -COLON- denotes ;
T931 112-116 CD denotes 2009
T930 110-111 -COMMA- denotes ,
T929 107-110 FW denotes al.
T928 104-106 FW denotes et
T927 98-103 NNP denotes Stupp
T926 96-97 -COLON- denotes ;
T925 92-96 CD denotes 2000
T924 90-91 -COMMA- denotes ,
T923 87-90 FW denotes al.
T922 84-86 FW denotes et
T921 75-83 NNP denotes Friedman
T920 74-75 -LRB- denotes (
T919 65-73 RB denotes annually
T918 60-64 NNP denotes U.S.
T917 56-59 DT denotes the
T916 53-55 IN denotes in
T915 44-52 NN denotes patients
T914 40-43 JJ denotes new
T913 33-39 CD denotes 12,500
T912 24-32 NN denotes afflicts
T911 13-23 JJ denotes multiforme
T1104 1012-1016 CD denotes 2012
T1103 1010-1011 -COMMA- denotes ,
T1102 1002-1010 NNP denotes Bjerkvig
T1101 998-1001 CC denotes and
T1100 986-997 NNP denotes Johannessen
T1099 984-985 -COLON- denotes ;
T1098 980-984 CD denotes 2012
T1097 978-979 -COMMA- denotes ,
T1096 975-978 FW denotes al.
T1095 972-974 FW denotes et
T1094 964-971 NNP denotes Happold
T1093 962-963 -COLON- denotes ;
T1092 958-962 CD denotes 2012
T1091 956-957 -COMMA- denotes ,
T1090 953-956 FW denotes al.
T1089 950-952 FW denotes et
T1088 945-949 NNP denotes Haar
T1087 944-945 -LRB- denotes (
T910 0-12 NN denotes Glioblastoma
R466 T915 T912 arg1Of patients,afflicts
R467 T915 T913 arg1Of patients,"12,500"
R468 T915 T914 arg1Of patients,new
R469 T915 T916 arg1Of patients,in
R470 T915 T919 arg1Of patients,annually
R471 T915 T920 arg1Of patients,(
R472 T918 T916 arg2Of U.S.,in
R473 T918 T917 arg1Of U.S.,the
R475 T921 T922 arg1Of Friedman,et
R476 T921 T923 arg1Of Friedman,al.
R477 T921 T924 arg1Of Friedman,","
R478 T921 T926 arg1Of Friedman,;
R479 T921 T932 arg1Of Friedman,;
R480 T925 T924 arg2Of 2000,","
R481 T927 T926 arg2Of Stupp,;
R482 T927 T928 arg1Of Stupp,et
R483 T927 T929 arg1Of Stupp,al.
R484 T927 T930 arg1Of Stupp,","
R485 T931 T930 arg2Of 2009,","
R486 T933 T932 arg2Of Silber,;
R487 T933 T934 arg1Of Silber,et
R488 T933 T935 arg1Of Silber,al.
R489 T933 T936 arg1Of Silber,","
R490 T937 T936 arg2Of 2012,","
R492 T939 T940 arg1Of Glioblastoma,(
R493 T939 T943 arg1Of Glioblastoma,is
R494 T939 T945 arg1Of Glioblastoma,lethal
R495 T941 T940 arg2Of GBM,(
R496 T942 T940 arg3Of ),(
R497 T943 T947 arg1Of is,and
R498 T945 T943 arg2Of lethal,is
R499 T945 T944 arg1Of lethal,highly
R500 T947 T946 arg1Of and,","
R501 T947 T955 arg1Of and,and
R502 T951 T948 arg1Of expectancy,the
R503 T951 T949 arg1Of expectancy,average
R504 T951 T950 arg1Of expectancy,survival
R505 T951 T952 arg1Of expectancy,is
R506 T951 T953 arg1Of expectancy,14.6 months
R507 T952 T947 arg2Of is,and
R508 T953 T952 arg2Of 14.6 months,is
R509 T955 T954 arg1Of and,","
R510 T960 T956 arg1Of rate,the
R511 T960 T957 arg1Of rate,overall
R512 T960 T958 arg1Of rate,5-year
R513 T960 T959 arg1Of rate,survival
R514 T960 T961 arg1Of rate,for
R515 T960 T963 arg1Of rate,is
R516 T962 T961 arg2Of GBM,for
R517 T963 T955 arg2Of is,and
R518 T963 T967 arg1Of is,(
R519 T965 T964 arg1Of 9.8,only
R520 T966 T963 arg2Of %,is
R521 T966 T965 arg1Of %,9.8
R522 T968 T967 arg2Of Friedman,(
R523 T968 T969 arg1Of Friedman,et
R524 T968 T970 arg1Of Friedman,al.
R525 T968 T971 arg1Of Friedman,","
R526 T968 T973 arg1Of Friedman,;
R527 T972 T971 arg2Of 2000,","
R528 T974 T973 arg2Of Stupp,;
R529 T974 T975 arg1Of Stupp,et
R530 T974 T976 arg1Of Stupp,al.
R531 T974 T977 arg1Of Stupp,","
R532 T978 T977 arg2Of 2009,","
R533 T979 T967 arg3Of ),(
R534 T981 T980 arg1Of levels,High
R535 T981 T982 arg1Of levels,of
R536 T981 T991 arg1Of levels,are
R537 T981 T993 arg2Of levels,seen
R538 T983 T984 arg1Of resistance,to
R539 T983 T988 arg1Of resistance,and
R540 T987 T984 arg2Of modalities,to
R541 T987 T985 arg1Of modalities,current
R542 T987 T986 arg1Of modalities,therapeutic
R543 T988 T982 arg2Of and,of
R544 T990 T988 arg2Of relapse,and
R545 T990 T989 arg1Of relapse,cancer
R546 T993 T991 arg2Of seen,are
R547 T993 T992 arg1Of seen,frequently
R548 T993 T994 arg1Of seen,in
R549 T993 T996 arg1Of seen,(
R550 T995 T994 arg2Of patients,in
R551 T997 T996 arg2Of Haar,(
R552 T997 T998 arg1Of Haar,et
R553 T997 T999 arg1Of Haar,al.
R554 T997 T1000 arg1Of Haar,","
R555 T997 T1002 arg1Of Haar,;
R556 T1001 T1000 arg2Of 2012,","
R557 T1003 T1002 arg2Of Happold,;
R558 T1003 T1004 arg1Of Happold,et
R559 T1003 T1005 arg1Of Happold,al.
R560 T1003 T1006 arg1Of Happold,","
R561 T1007 T1006 arg2Of 2012,","
R562 T1008 T996 arg3Of ),(
R567 T1012 T1009 arg1Of therapy,The
R572 T1019 T1020 arg1Of surgery,","
R573 T1020 T1023 arg1Of ",",and
R574 T1021 T1020 arg2Of radiation,","
R575 T1023 T1016 arg2Of and,includes
R576 T1023 T1022 arg1Of and,","
R577 T1024 T1023 arg2Of treatment,and
R578 T1024 T1025 arg1Of treatment,with
R579 T1030 T1025 arg2Of temozolomide,with
R580 T1030 T1026 arg1Of temozolomide,the
R581 T1030 T1027 arg1Of temozolomide,monofunctional
R582 T1030 T1028 arg1Of temozolomide,alkylating
R583 T1030 T1029 arg1Of temozolomide,agent
R584 T1030 T1031 arg1Of temozolomide,(
R585 T1030 T1034 arg1Of temozolomide,(
R586 T1032 T1031 arg2Of TMZ,(
R587 T1033 T1031 arg3Of ),(
R588 T1035 T1034 arg2Of Friedman,(
R589 T1035 T1036 arg1Of Friedman,et
R590 T1035 T1037 arg1Of Friedman,al.
R591 T1035 T1038 arg1Of Friedman,","
R592 T1035 T1040 arg1Of Friedman,;
R593 T1039 T1038 arg2Of 2000,","
R594 T1041 T1040 arg2Of Nishikawa,;
R595 T1041 T1042 arg1Of Nishikawa,","
R596 T1043 T1042 arg2Of 2010,","
R597 T1044 T1034 arg3Of ),(
R598 T1046 T1045 arg1Of mechanisms,Multiple
R599 T1046 T1047 arg1Of mechanisms,are
R600 T1046 T1048 arg2Of mechanisms,involved
R601 T1048 T1047 arg2Of involved,are
R602 T1048 T1049 arg1Of involved,in
R603 T1052 T1049 arg2Of resistance,in
R604 T1052 T1050 arg1Of resistance,the
R605 T1052 T1051 arg1Of resistance,TMZ
R606 T1052 T1053 arg1Of resistance,","
R607 T1052 T1054 arg1Of resistance,which
R608 T1052 T1055 arg1Of resistance,may
R609 T1052 T1056 arg1Of resistance,include
R610 T1056 T1055 arg2Of include,may
R611 T1059 T1057 arg1Of cells,cancer
R612 T1059 T1058 arg1Of cells,stem
R613 T1059 T1060 arg1Of cells,","
R614 T1060 T1062 arg1Of ",",","
R615 T1061 T1060 arg2Of microRNAs,","
R616 T1062 T1065 arg1Of ",",","
R617 T1064 T1062 arg2Of efflux,","
R618 T1064 T1063 arg1Of efflux,drug
R619 T1065 T1069 arg1Of ",",","
R620 T1068 T1065 arg2Of repair,","
R621 T1068 T1066 arg1Of repair,DNA
R622 T1068 T1067 arg1Of repair,damage
R623 T1069 T1056 arg2Of ",",include
R624 T1069 T1072 arg1Of ",",under
R625 T1071 T1069 arg2Of cells,","
R626 T1071 T1070 arg1Of cells,tumor
R627 T1073 T1074 arg1Of hypoxia,","
R628 T1074 T1077 arg1Of ",",","
R629 T1076 T1074 arg2Of deacetylation,","
R630 T1076 T1075 arg1Of deacetylation,histone
R631 T1077 T1080 arg1Of ",",","
R632 T1079 T1077 arg2Of transition,","
R633 T1079 T1078 arg1Of transition,epithelial-mesenchymal
R634 T1080 T1084 arg1Of ",",and
R635 T1082 T1080 arg2Of kinase,","
R636 T1082 T1081 arg1Of kinase,STAT3
R637 T1084 T1072 arg2Of and,under
R638 T1084 T1083 arg1Of and,","
R639 T1086 T1084 arg2Of others,and
R640 T1086 T1085 arg1Of others,many
R641 T1086 T1087 arg1Of others,(
R642 T1088 T1087 arg2Of Haar,(
R643 T1088 T1089 arg1Of Haar,et
R644 T1088 T1090 arg1Of Haar,al.
R645 T1088 T1091 arg1Of Haar,","
R646 T1088 T1093 arg1Of Haar,;
R647 T1088 T1099 arg1Of Haar,;
R648 T1092 T1091 arg2Of 2012,","
R649 T1094 T1093 arg2Of Happold,;
R650 T1094 T1095 arg1Of Happold,et
R651 T1094 T1096 arg1Of Happold,al.
R652 T1094 T1097 arg1Of Happold,","
R653 T1098 T1097 arg2Of 2012,","
R654 T1100 T1101 arg1Of Johannessen,and
R655 T1101 T1099 arg2Of and,;
R656 T1101 T1103 arg1Of and,","
R657 T1101 T1105 arg1Of and,;
R658 T1101 T1111 arg1Of and,;
R659 T1102 T1101 arg2Of Bjerkvig,and
R660 T1104 T1103 arg2Of 2012,","
R661 T1106 T1105 arg2Of Kitange,;
R662 T1106 T1107 arg1Of Kitange,et
R663 T1106 T1108 arg1Of Kitange,al.
R664 T1106 T1109 arg1Of Kitange,","
R665 T1110 T1109 arg2Of 2012,","
R666 T1112 T1111 arg2Of Kohsaka,;
R667 T1112 T1113 arg1Of Kohsaka,et
R668 T1112 T1114 arg1Of Kohsaka,al.
R669 T1112 T1115 arg1Of Kohsaka,","
R670 T1112 T1117 arg1Of Kohsaka,;
R671 T1116 T1115 arg2Of 2012,","
R672 T1118 T1117 arg2Of Zhang,;
R673 T1118 T1119 arg1Of Zhang,et
R674 T1118 T1120 arg1Of Zhang,al.
R675 T1118 T1121 arg1Of Zhang,","
R676 T1122 T1121 arg2Of 2012b,","
R677 T1123 T1087 arg3Of ),(
R464 T915 T910 arg1Of patients,Glioblastoma
R465 T915 T911 arg1Of patients,multiforme
R474 T921 T920 arg2Of Friedman,(
R491 T938 T920 arg3Of ),(
R563 T1012 T1010 arg1Of therapy,current
R564 T1012 T1011 arg1Of therapy,standard
R565 T1012 T1013 arg1Of therapy,for
R566 T1012 T1016 arg1Of therapy,includes
R568 T1014 T1013 arg2Of GBM,for
R569 T1016 T1015 arg1Of includes,mainly
R570 T1019 T1017 arg1Of surgery,maximum
R571 T1019 T1018 arg1Of surgery,debulking

2_test

Id Subject Object Predicate Lexical cue
23459853-10914698-38778478 92-96 10914698 denotes 2000
23459853-19269895-38778479 112-116 19269895 denotes 2009
23459853-22244911-38778480 133-137 22244911 denotes 2012
23459853-10914698-38778481 305-309 10914698 denotes 2000
23459853-19269895-38778482 325-329 19269895 denotes 2009
23459853-22228201-38778483 457-461 22228201 denotes 2012
23459853-10914698-38778484 669-673 10914698 denotes 2000
23459853-20885105-38778485 686-690 20885105 denotes 2010
23459853-22228201-38778486 958-962 22228201 denotes 2012
23459853-22594898-38778487 1012-1016 22594898 denotes 2012
23459853-22675172-38778488 1034-1038 22675172 denotes 2012
23459853-22532597-38778489 1056-1060 22532597 denotes 2012

UBERON-AE

Id Subject Object Predicate Lexical cue
T873 890-901 http://purl.obolibrary.org/obo/UBERON_0003104 denotes mesenchymal

GO-BP

Id Subject Object Predicate Lexical cue
T1971 879-912 http://purl.obolibrary.org/obo/GO_0001837 denotes epithelial-mesenchymal transition
T1970 879-912 http://purl.obolibrary.org/obo/GO_0060317 denotes epithelial-mesenchymal transition
T1969 879-912 http://purl.obolibrary.org/obo/GO_0060231 denotes epithelial-mesenchymal transition
T1968 879-912 http://purl.obolibrary.org/obo/GO_0010717 denotes epithelial-mesenchymal transition
T1967 856-877 http://purl.obolibrary.org/obo/GO_0016575 denotes histone deacetylation

GO-CC

Id Subject Object Predicate Lexical cue
T2044 810-827 http://purl.obolibrary.org/obo/GO_1990391 denotes DNA damage repair
T2035 835-840 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T2034 779-784 http://purl.obolibrary.org/obo/GO_0005623 denotes cells

sentences

Id Subject Object Predicate Lexical cue
T879 693-1083 Sentence denotes Multiple mechanisms are involved in the TMZ resistance, which may include cancer stem cells, microRNAs, drug efflux, DNA damage repair, tumor cells under hypoxia, histone deacetylation, epithelial-mesenchymal transition, STAT3 kinase, and many others (Haar et al., 2012; Happold et al., 2012; Johannessen and Bjerkvig, 2012; Kitange et al., 2012; Kohsaka et al., 2012; Zhang et al., 2012b).
T878 486-692 Sentence denotes The current standard therapy for GBM mainly includes maximum debulking surgery, radiation, and treatment with the monofunctional alkylating agent temozolomide (TMZ) (Friedman et al., 2000; Nishikawa, 2010).
T877 332-485 Sentence denotes High levels of resistance to current therapeutic modalities and cancer relapse are frequently seen in patients (Haar et al., 2012; Happold et al., 2012).
T876 140-331 Sentence denotes Glioblastoma (GBM) is highly lethal, and the average survival expectancy is 14.6 months, and the overall 5-year survival rate for GBM is only 9.8% (Friedman et al., 2000; Stupp et al., 2009).
T875 0-139 Sentence denotes Glioblastoma multiforme afflicts 12,500 new patients in the U.S. annually (Friedman et al., 2000; Stupp et al., 2009; Silber et al., 2012).
T11 0-139 Sentence denotes Glioblastoma multiforme afflicts 12,500 new patients in the U.S. annually (Friedman et al., 2000; Stupp et al., 2009; Silber et al., 2012).
T12 140-331 Sentence denotes Glioblastoma (GBM) is highly lethal, and the average survival expectancy is 14.6 months, and the overall 5-year survival rate for GBM is only 9.8% (Friedman et al., 2000; Stupp et al., 2009).
T13 332-485 Sentence denotes High levels of resistance to current therapeutic modalities and cancer relapse are frequently seen in patients (Haar et al., 2012; Happold et al., 2012).
T14 486-692 Sentence denotes The current standard therapy for GBM mainly includes maximum debulking surgery, radiation, and treatment with the monofunctional alkylating agent temozolomide (TMZ) (Friedman et al., 2000; Nishikawa, 2010).
T15 693-1083 Sentence denotes Multiple mechanisms are involved in the TMZ resistance, which may include cancer stem cells, microRNAs, drug efflux, DNA damage repair, tumor cells under hypoxia, histone deacetylation, epithelial-mesenchymal transition, STAT3 kinase, and many others (Haar et al., 2012; Happold et al., 2012; Johannessen and Bjerkvig, 2012; Kitange et al., 2012; Kohsaka et al., 2012; Zhang et al., 2012b).